ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY)

Historical Holders from Q4 2020 to Q3 2025

Symbol
SPRY on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
98.6M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
83.6M
Holdings value
$840M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
187
Number of buys
111
Number of sells
-85
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 11.1% $111M 10.9M RA Capital Management, L.P. 29 Sep 2025
Flynn James E 7.75% -11.6% $135M -$18.1M 7.61M -11.9% Deerfield Management Company, L.P. 30 Jul 2025

Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 83.6M $840M -$93.3M $10.05 187
2025 Q2 84.5M $1.48B +$150M $17.45 185
2025 Q1 76.2M $959M +$63.8M $12.58 182
2024 Q4 71.3M $752M +$68.1M $10.55 163
2024 Q3 63.8M $926M +$31.1M $14.50 148
2024 Q2 62.6M $533M +$21.9M $8.51 112
2024 Q1 59.9M $612M -$16.2M $10.22 113
2023 Q4 65.4M $359M -$2.78M $5.48 99
2023 Q3 66.5M $251M +$38.8M $3.78 94
2023 Q2 55.1M $369M +$11.2M $6.70 92
2023 Q1 53.4M $348M +$19.6M $6.51 88
2022 Q4 50.2M $428M +$173M $8.53 72
2022 Q3 30.4M $160M +$24.5M $5.28 58
2022 Q2 26.1M $111M -$388K $4.24 60
2022 Q1 27M $94.7M -$19.6M $3.51 66
2021 Q4 30.1M $200M -$13.2M $6.66 71
2021 Q3 28.9M $288M -$42.5M $9.98 73
2021 Q2 28M $865M +$5.24M $30.89 74
2021 Q1 27.7M $1.21B +$139M $43.63 67
2020 Q4 24.4M $1.13B +$1.12B $46.34 61